Another targeted drug, Rigosertib, that was originally identified as a polo-like kinase 1 (Plk1) inhibitor [15] was recently shown as a potent microtubule depolymerizing agent, exhibiting its cytotoxic properties for cancer cells via tubulin depolymerization as a consequence of its binding to the tubulin [16], thereby highlighting the possibility of developing anticancer drugs with a dual-mode of action and effectively inhibiting kinase activity and microtubule function. Here, PLK1 is linked to cancer.